Renal Denervation Side Effects: What Are the Risks?

Renal denervation carries a safety profile broadly comparable to other catheter-based procedures, with no significant increase in major adverse events over sham procedures in the largest meta-analyses. A 2024 systematic review and meta-analysis pooling data from sham-controlled trials found no meaningful difference in vascular complications, renal artery stenosis, hypertensive crises, or death between people who received the procedure and those who received a sham.¹ That said, clinical trials exclude many of the patients who end up receiving the procedure in the real world, and post-marketing surveillance tells a somewhat grittier story. The risks are real, even if they are uncommon, and understanding them matters before consenting to a procedure whose blood-pressure benefits are modest in absolute terms.

Vascular Complications Are the Most Common Problem

The biggest category of side effects involves damage to blood vessels, either at the groin access site or inside the renal arteries themselves. A post-marketing analysis of the FDA’s adverse-event database found that vascular complications accounted for just under half of all reported events. The most serious included renal artery dissection (small tears in the artery wall), renal artery thrombosis (blood clots forming inside the artery), and vasospasm (sudden tightening of the artery). One access-site pseudoaneurysm was complicated by hemorrhagic shock, a life-threatening drop in blood pressure from internal bleeding.²

To put those numbers in context, the FDA database captures voluntarily reported events, so it tends to pick up the worst outcomes rather than the full denominator of procedures performed. Still, the types of complications it reveals are instructive. Dissections were managed with balloon angioplasty or stent placement. Thrombosis cases required clot-dissolving drugs or mechanical clot removal. Vasospasm was typically treated with nitroglycerin injected directly into the artery. These are serious interventions, but they were treatable in all reported cases.

What Happens to the Artery Wall During the Procedure

Imaging studies performed immediately after catheter-based denervation show that the procedure routinely causes microscopic changes to the artery. An optical coherence tomography study using multiple catheter types found vasospasm in roughly 40% of treated arteries, along with wall swelling and occasional small thrombus formation.³ A separate animal study confirmed similar acute changes, including edema and thrombus, though frank dissection was uncommon.⁴

The reassuring side of this picture is that most of these acute injuries heal. Damaged endothelium (the inner lining of the artery) generally recovers within about a week, and deeper arterial wall changes resolve within roughly six months.⁵ The less reassuring side is that these findings come from controlled trial conditions with experienced operators. In real-world practice, with varying levels of operator skill and patient anatomy, the healing timeline is less certain.

Renal Artery Stenosis Can Develop Months Later

One of the more concerning risks is renal artery stenosis, a narrowing of the artery that can appear well after the procedure. Unlike the acute injuries described above, stenosis tends to develop insidiously. In one published case, imaging at six months showed no narrowing, but the patient returned with recurrent resistant hypertension 28 months after denervation. Repeat imaging revealed that stenosis had developed near the most proximal ablation point.⁶ In another case, a patient developed severe bilateral renal artery stenosis just nine months after radiofrequency denervation, presenting with a hypertensive crisis, flash pulmonary edema, and worsening kidney function.⁷

A meta-analysis focused on renal artery damage after radiofrequency denervation identified 25 cases where patients needed stent placement at least one month after the procedure. About a third of those patients had some degree of pre-existing renal artery narrowing, which raises the question of whether the procedure accelerated a problem that was already brewing or created an entirely new one.⁸ Either way, the takeaway is that follow-up imaging matters, and anyone who experiences a resurgence in blood pressure after denervation should have their renal arteries re-evaluated.

Impact on Kidney Function

Given that the procedure involves heating tissue inside the arteries that supply the kidneys, a natural worry is whether it damages the kidneys themselves. The overall evidence here is encouraging. The large meta-analysis of sham-controlled trials found that changes in estimated kidney filtration rate were essentially the same in the denervation and sham groups.¹ A review in the American Journal of Kidney Diseases echoed this, noting that kidney function appeared unaffected by denervation even in patients who already had reduced kidney function.⁹

There is a caveat worth knowing about, however. Most pivotal trials excluded patients with severely reduced kidney function (filtration rates below 45 mL/min/1.73 m²), in part because of concerns about the iodinated contrast dye used during the procedure.⁹ Contrast dye itself can be toxic to kidneys that are already struggling, so the safety data for people with more advanced kidney disease comes from smaller, less rigorous studies rather than the large sham-controlled trials.

What About People Who Already Have Kidney Disease

For people with mild to moderate chronic kidney disease, the available evidence is cautiously optimistic. A systematic review and meta-analysis of denervation in this population found that kidney filtration rates did not significantly change at 6, 12, or 24 months after the procedure, with a trend that some researchers have interpreted as a possible interruption of the natural decline expected with chronic kidney disease. The overall procedural complication rate in this group was around 5%.¹⁰ A separate meta-analysis found a significant reduction in urinary albumin (a marker of kidney damage) at 3 and 6 months after denervation, with few major complications.¹¹

These findings need a dose of realism, though. The patient numbers in chronic kidney disease studies are small compared with the main hypertension trials, and the follow-up periods are shorter. Whether the procedure remains safe over 5 or 10 years in someone whose kidneys are already compromised is simply unknown. If you have significant kidney disease and are considering denervation, the contrast dye exposure alone is a risk that warrants careful discussion with your nephrologist.

Effects on Exercise and Heart Rate

Because renal denervation disrupts the sympathetic nerves running to and from the kidneys, there is a reasonable question about whether it affects the body’s broader fight-or-flight responses, particularly during exercise. One early study found that resting heart rate dropped by about 4 beats per minute after the procedure, which is a modest change. Crucially, maximum heart rate during exercise and the ability to increase heart rate during exertion were unaffected. Heart rate recovery after exercise actually improved slightly.¹²

This is worth flagging because some patients worry that ablating renal nerves might leave them unable to mount a normal cardiovascular response to physical activity. The evidence suggests otherwise: the procedure targets the nerve pathways around the renal arteries specifically, and the body’s broader autonomic regulation of the heart during exercise appears to be left intact. The small drop in resting heart rate is actually considered a positive sign, as it reflects a reduction in the chronic sympathetic overdrive that contributes to resistant hypertension.

Do the Nerves Grow Back

A persistent question in the field is whether the destroyed nerves eventually regenerate, potentially erasing the blood-pressure benefits. Animal research shows that nerve tissue does attempt to regrow, but the results are disorganized. In a study of pigs followed for up to 90 days after denervation, researchers observed that by one month, the body was laying down scar tissue at ablation sites. By three months, prominent tangles of nerve tissue called neuromas had formed, but their architecture was chaotic and disorganized rather than functional. The investigators concluded that meaningful functional regeneration was unlikely based on this disrupted anatomy.¹³

In humans, the question is harder to answer directly because you cannot biopsy renal nerves in living patients. Indirect evidence comes from the observation that blood-pressure reductions in some trials have been sustained out to 36 or even 48 months. However, a subset of patients do see their blood pressure creep back up over time, and whether that represents nerve regrowth, disease progression, or some other factor remains debated. Neuroma formation itself is not typically symptomatic, but the possibility that nerve regrowth could restore the very sympathetic overdrive the procedure was designed to interrupt is a theoretical long-term concern that lacks a clear human answer.

How Anatomy Affects Risk

Not everyone’s renal arteries look the same, and anatomical variation is a meaningful factor in both the effectiveness and the safety of denervation. Accessory renal arteries (extra arteries supplying the kidney), early branching, and tortuous (sharply curved) vessels can all complicate catheter placement and energy delivery.¹⁴ In the FDA post-marketing database, tortuous anatomy was specifically flagged in at least one case of renal artery thrombosis that led to incomplete treatment.²

Pre-procedural imaging with CT angiography or MR angiography is standard practice to map the renal vasculature before the procedure. If you have significant anatomical variants, the proceduralist may need to adjust the approach, use a different catheter system, or in some cases decide that the anatomy makes denervation too risky or unlikely to succeed. This is one area where the conversation with your interventional team before the procedure is particularly important.

Differences Between Energy Types

Two main energy modalities are used for renal denervation: radiofrequency and ultrasound. Radiofrequency systems deliver heat through direct contact between the catheter tip and the arterial wall. Ultrasound systems work differently: a transducer emits sound waves circumferentially from within a fluid-filled balloon, generating heat deeper in the tissue while the balloon’s cooling fluid protects the inner surface of the artery.¹⁵

In theory, the ultrasound approach should cause less intimal (inner wall) damage because the energy does not require direct tissue contact. The radiofrequency approach, by contrast, applies energy right at the wall surface, which is why the early optical coherence tomography studies showed such high rates of wall edema and vasospasm. A newer experimental approach using microwave energy has shown promise in animal studies for reaching the nerves without injuring the inner and middle layers of the artery at all, though no heating was observed beyond the fat layer surrounding the kidney.¹⁶ Microwave denervation remains experimental and is not yet available clinically.

From a meta-analytic standpoint, head-to-head comparisons of radiofrequency and ultrasound have focused primarily on blood-pressure lowering rather than safety endpoints, so definitive statements about which modality is “safer” are premature. Both have been used in sham-controlled trials without significant safety signals compared to sham. The practical point for patients is that the specific device used may influence the type of acute arterial injury (more surface-level changes with radiofrequency, potentially fewer with ultrasound), but both carry the same general categories of risk.

The Role of Operator Experience

Renal denervation is a catheter procedure performed by interventional cardiologists, interventional radiologists, or sometimes vascular surgeons. Like any procedural skill, there is a learning curve. The American Heart Association’s scientific statement on renal denervation emphasizes that multidisciplinary teams including hypertension specialists and adequately trained proceduralists are crucial for safe practice.¹⁷

This is not just bureaucratic language. The complications reported in post-marketing databases come disproportionately from the early period after a device enters the market, when operators are still gaining familiarity. How many ablation points are placed, where they are positioned, how long energy is applied, and how the catheter is navigated through tortuous anatomy all depend on operator judgment. If you are considering denervation, asking your physician about their procedural volume and institutional experience is a reasonable and encouraged step. Centers that have performed more procedures tend to have lower complication rates, a pattern seen across virtually every catheter-based intervention.

Comparing Risks to the Alternative

Renal denervation is typically offered to people whose blood pressure remains dangerously elevated despite multiple medications. That context matters when weighing risks. The side effects of three, four, or five antihypertensive medications taken daily for decades are not trivial: they include chronic fatigue, dizziness, erectile dysfunction, electrolyte disturbances, and kidney stress from some drug classes. Non-adherence is also a major problem with complex medication regimens, and uncontrolled hypertension itself carries risks of stroke, heart failure, and kidney failure that dwarf the procedural risks of denervation.

This does not mean denervation is risk-free or appropriate for everyone. It means the relevant comparison is not “procedure vs. no procedure” but “procedure vs. continuing to live with poorly controlled blood pressure or with the cumulative burden of polypharmacy.” In the sham-controlled trials, the rates of major adverse events were similar between the two groups precisely because both groups were already living with the risks of severe hypertension and its treatment.¹

What Follow-Up Looks Like

After denervation, you will not simply walk away and stop monitoring. Standard post-procedural care includes regular blood-pressure checks (both office and ambulatory), periodic assessment of kidney function through blood tests, and imaging of the renal arteries at some point within the first year to check for stenosis. Medications are typically not stopped immediately; instead, they are tapered gradually under physician supervision as the blood-pressure-lowering effect of denervation becomes apparent over weeks to months.

If blood pressure begins climbing again after an initial improvement, this does not automatically mean the procedure “failed.” It may reflect incomplete denervation (not all relevant nerve fibers were disrupted), progression of underlying disease, medication non-adherence, or the theoretical possibility of partial nerve regrowth. In practice, some patients need a second procedure or continued medication adjustment. The procedure is one piece of a broader hypertension management strategy, not a standalone cure, and long-term follow-up with a hypertension specialist remains essential regardless of how well the initial procedure appears to work.